Responsable: José López Barneo
Tipo de Proyecto/Ayuda: 6º Programa Marco de la U.E.
Referencia: LSHM-CT-2005-018725
Web: http://cordis.europa.eu/projects/rcn/78433_en.html
Fecha de Inicio: 01-01-2006
Fecha de Finalización: 31-12-2009

Empresa/Organismo financiador/es:

• Commission of the European Communities (Research Directorate-General)

Socios:

• Justus Liebig Universitat-Giessen (Seeger Werner)
• Alphalyse A/S (Thomas Kofoed)
• Altana Pharma AG (Christian Schudt)
• Dr. Riethmüller M/R/S GmbH (Hilde Riethmüller-Winzen)
• Dualsystems Biotech AG (Michael Hottiger)
• Genolyze Ltd. (Marko Mäenpää)
• Assistance Publique Hopitaux de Paris (Gérald Simonneau)
• Hospital Clinic i Provincial de Barcelona (Joan Albert Barberà)
• Imperial College of Science, Technology and Medicine, London (Martin Wilkins)
• Institut National de la Santé et de la Recherché Médicale (Serge Adnot)
• Charité University Medicine Berlin (Wolfgang M. Kuebler)
• LEA Medizintechnik GmbH (Alfons Krug)
• Luxcel Biosciences Ltd. (Dmitri Boris Papkovsky)
• Medical School of Hannover (Tobias Welte)
• Medical University Graz (Horst Olschewski)
• Medical University of Vienna (Irene Lang)
• BioSpring GmbH (Hüseyin Aygün)
• North Glasgow Trust (Andrew Peacock)
• The Chancellor, Masters and Scholars of the University of Oxford (Christopher W. Pugh)
• TransMIT Gesellschaft für Technologietransfer mbH (Christian Schulze)
• University of Heidelberg (Bart Janssen)
• Université Libre de Bruxelles (Robert Naeije)
• University College London (James Mitchell Leiper)
• Alma Mater Studiorum - Universitá di Bologna (Nazzareno Galiè)
• The Chancellor, Masters and Scholars of the University of Cambridge (Nicholas Morrell)
• Universitätsklinikum Duisburg-Essen (Joachim Fandrey)
• University of Glasgow (Margartet MacLean)
• University of Ioannina (Savvas Christoforidis)
• King´s College London (Richard Charles Trembath)
• University of Zurich (Max Gassmann)

Equipo:

• Investigadores:
  • Antonio Gonzalo Castellano Orozco
  • Juan Ureña López
• Becarios:
  • Patricia Ortega Sáenz

Resumen del proyecto:

Pulmonary hypertension (PH) describes devastating diseases, comprising idiopathic and secondary forms, which cause breathlessness and premature death, representing a major burden on healthcare systems. Extensive lung vascular remodelling with loss of vessel patency is the underlying pathomechanism. PULMOTENSION integrates the top EU Centres in PH and lung vascular biology in a multidisciplinary approach, aiming to combat and finally cure PH. The expertise of all members extends from the initial discovery of gene mutations causative of PH to having established new therapeutic regimen of PH. We will uncover underlying molecular pathways, identify distinct targets for anti-remodelling therapy, foster drug development based on these targets, and test these new treatment options in preclinical and clinical trials. The presented project includes a) genetics of PH, b) functional genomics and proteomics to unravel the molecular pathways underlying vascular remodelling, c) characterisation of the cross-talk between different cells and signalling pathways involved, d) preclinical trials in PH models including transgenics, e) a European PH Tissue Bank and Registry, f) conversion of target discovery into drug design and exploitation, g) development of non-invasive clinical tools for monitoring lung vascular remodelling in patients, h) a Clinical Trial Network to conduct phase I/II(III) studies focussing on anti- and reversal of remodelling in PH patients, and i) promotion of a world-leading infrastructure for scientific and technical competence in the field of PH, including training and mobility programs, technology transfer in alliance with industry and exploitation facilities. Gender issues will be particularly addressed, as many PH forms have a female preponderance.